Table. Demographic and Histopathologic Characteristics of Study Patientsa .
| Characteristic | EGFR-TKI therapy cohorts | Chemotherapy cohorts | |||
|---|---|---|---|---|---|
| Training cohort (n = 145) | Validation cohort 1 (n = 101) | Validation cohort 2 (n = 96) | EGFR variant positive (n = 56) | EGFR wild type (n = 67) | |
| No. of CT sections | 3481 | 1855 | 868 | NA | NA |
| Sex | |||||
| Male | 58 (40.0) | 41 (40.6) | 41 (42.7) | 30 (53.6) | 57 (85.1) |
| Female | 87 (60.0) | 60 (59.4) | 55 (57.3) | 26 (46.4) | 10 (14.9) |
| Age, y | |||||
| ≤65 | 84 (57.9) | 66 (65.3) | 66 (68.8) | 43 (76.8) | 60 (89.6) |
| >65 | 61 (42.1) | 35 (34.7) | 30 (31.2) | 13 (23.2) | 7 (10.4) |
| PS score | |||||
| ≥2 | 100 (69.0) | 68 (46.9) | 62 (64.6) | 43 (76.8) | 39 (58.2) |
| <2 | 45 (31.0) | 33 (53.1) | 34 (35.4) | 13 (23.2) | 28 (41.8) |
| PFS, median (SD), mo | 10.1 (15.0) | 9.2 (9.0) | 8.2 (7.9) | 4.5 (4.7) | 3.6 (3.6) |
| EGFR variant | |||||
| EGFR 19Del | 72 (49.7) | 60 (59.4) | 41 (42.7) | 21 (37.5) | NA |
| EGFR 21L858R | 59 (40.7) | 35 (34.6) | 48 (50.0) | 30 (53.6) | NA |
| Other | 14 (9.6) | 6 (6.0) | 7 (7.3) | 5 (8.9) | NA |
| Tobacco use | |||||
| Smoker | 60 (41.3) | 21 (20.8) | 17 (17.7) | 14 (25.0) | 55 (82.1) |
| Nonsmoker | 85 (58.7) | 80 (79.2) | 79 (82.3) | 42 (75.0) | 12 (17.9) |
| Histopathology | |||||
| Adenocarcinoma | 135 (93.1) | 99 (98.0) | 92 (95.8) | 31 (55.4) | 12 (17.9) |
| SCC | 9 (6.2) | 1 (1.0) | 3 (3.1) | 25 (44.6) | 55 (82.1) |
| Other | 1 (0.7) | 1 (1.0) | 1 (1.1) | 0 | 0 |
Abbreviations: EGFR, epidermal growth factor receptor; CT, computed tomography; NA, not applicable; PFS, progression-free survival; PS, performance status; SCC, squamous cell carcinoma; TKI, tyrosine kinase inhibitor.
a
Data are presented as number (percentage) of patients unless otherwise indicated.